Syed Faiz I, Couriel Daniel R, Frame David, Srinivasan Ashok
Division of Neuroradiology, Department of Radiology, VA Ann Arbor Health System, University of Michigan Health System, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA.
BMT Program, Huntsman Cancer Center, University of Utah, 2000 Circle of Hope. Office #2151, Salt Lake City, UT 84112, USA.
Hematol Oncol Clin North Am. 2016 Aug;30(4):887-98. doi: 10.1016/j.hoc.2016.03.009. Epub 2016 Jun 7.
Hematopoietic stem cell transplantation (SCT) is now commonly used to treat several hematologic and nonhematologic diseases. Central nervous system (CNS) complications post-transplantation occur commonly in the first year and result in increased mortality from infectious, toxic, metabolic, or vascular causes. Infections secondary to aspergillus, toxoplasma and viruses cause many of the complications. Drug-related toxicities arising from conditioning regimens and graft-versus-host disease prophylaxis, as well as intraparenchymal hemorrhage, are not uncommon and can result in increased morbidity. Secondary CNS cancers have a higher incidence 5 or more years after allogeneic SCT.
造血干细胞移植（SCT）目前常用于治疗多种血液系统和非血液系统疾病。移植后中枢神经系统（CNS）并发症通常在第一年出现，可导致因感染、中毒、代谢或血管原因引起的死亡率增加。曲霉菌、弓形虫和病毒继发的感染导致许多并发症。预处理方案和移植物抗宿主病预防措施引起的药物相关毒性，以及脑实质内出血并不少见，可导致发病率增加。异基因造血干细胞移植后5年或更长时间，继发性中枢神经系统癌症的发病率较高。
